Please enable JavaScript
Powered by Benchmark MaSS English, Author at Matribhumi Samachar English - Page 398 of 2581
Thursday, January 15 2026 | 08:12:40 PM
Home / MaSS English (page 398)

MaSS English

DJflowers Shop Launches Premium Flower Subscription with Personal Florist Concierge Service

Dubai, United Arab Emirates–(Newsfile Corp. – October 30, 2025) – Dubai’s flower delivery and subscription Double Jenya Flower Shop introduces fully customized flower subscriptions, plus venue decoration and balloon services that transform any occasion into an unforgettable experience.  What started as a family passion in 2021 has blossomed into one …

Read More »

CSE Bulletin: MOC Eligibility Update

Toronto, Ontario–(Newsfile Corp. – October 30, 2025) – The following CSE-Listed symbol will become MOC Eligible as detailed below. Symbol Company Name Effective Date ANDC Andina Copper Corporation Tuesday November 4, 2025 ARMY Armory Mining Corp. DMED Diagnamed Holdings Corp. GURN Global Uranium Corp. SPIR Spirit Blockchain Capital Inc. SX …

Read More »

CSE Bulletin: Resumption – Seahawk Ventures Inc. (SEAG.X)

Toronto, Ontario–(Newsfile Corp. – Le 30 octobre/October 2025) – Seahawk Ventures Inc. (“Seahawk”), has announced that further to its press release dated June 18, 2025, it has terminated the share exchange agreement dated June 17, 2025 with Alluvial Capital Corp. and its shareholders as well as the amended and restated …

Read More »

Magma Silver Niñobamba Phase 2 Work Program Results

Vancouver, British Columbia–(Newsfile Corp. – October 30, 2025) – Magma Silver Corp. (TSXV: MGMA) (OTCQB: MAGMF) (FSE: BC21) (WKN: A411DV) (the “Company” or “Magma“) is pleased to provide an update on the Q3 ongoing work program on the Joramina and Randypata properties on the advanced Niñobamba silver gold project in …

Read More »

Hemostemix’s Boots on the Ground in Florida October Update

Calgary, Alberta–(Newsfile Corp. – October 30, 2025) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient’s own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from pain related to angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive …

Read More »